Gene therapy for sickle cell disease: moving from the bench to the bedside.

Abstract

Gene therapy as a potential cure for sickle cell disease (SCD) has long been pursued, given that this hemoglobin (Hb) disorder results from a single point mutation. Advances in genomic sequencing have increased the understanding of Hb regulation, and discoveries of molecular tools for genome modification of hematopoietic stem cells have made gene therapy for SCD possible. Gene-addition strategies using gene transfer vectors have been optimized over the past few decades to increase expression of normal or antisickling globins as strategies to ameliorate SCD. Many hurdles had to be addressed before clinical translation, including collecting sufficient stem cells for gene modification, increasing expression of transferred genes to a therapeutic level, and conditioning patients in a safe manner that enabled adequate engraftment of gene-modified cells. The discovery of genome editors that make precise modifications has further advanced the safety and efficacy of gene therapy, and a rapid movement to clinical trial has undoubtedly been supported by lessons learned from optimizing gene-addition strategies. Current gene therapies being tested in clinical trial require significant infrastructure and expertise, given that cells must be harvested from and chemotherapy administered to patients who often have significant organ dysfunction and that gene-modification takes place ex vivo in specialized facilities. For these therapies to realize their full potential, they would have to be portable, safe, and efficient, to make an in vivo-based approach attractive. In addition, adequate resources for SCD screening and access to standardized care are critically important for gene therapy to be a viable treatment option for SCD.

• Authors: Allistair A Abraham, John F Tisdale
• Journal: Blood (Blood) Vol. 138 Issue 11 Pg. 932-941 (09 16 2021) ISSN: 1528-0020 [Electronic] United States
• PMID: 34232993 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Hemoglobin, Sickle
• beta-Globins
• gamma-Globins

Topics

• Anemia, Sickle Cell (genetics, therapy)
• Animals
• Clinical Trials as Topic
• Gene Editing (methods)
• Genetic Therapy (methods)
• Genetic Vectors (genetics, therapeutic use)
• Hemoglobin, Sickle (genetics)
• Humans
• beta-Globins (genetics)
• gamma-Globins (genetics)